{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:08:38Z","timestamp":1775196518782,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program, China","award":["2023YFC2606000"],"award-info":[{"award-number":["2023YFC2606000"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and poses a substantial disease burden to infants, older adults, and immunocompromised populations. Methods: In this study, a recombinant vaccinia virus (rMVA-RSV preF) was constructed based on the modified vaccinia virus Ankara (MVA) platform by inserting a stabilized prefusion F protein gene of RSV into the MVA genome. The immunogenicity of rMVA-RSV preF and preF protein was evaluated in Balb\/c mice under different vaccination regimens. Results: A heterologous prime\u2013boost regimen, priming with rMVA-RSV preF and boosting with AS01E-adjuvanted preF protein, elicited robust cellular and humoral immune responses with a Th1 bias. This regimen significantly enhanced immunogenicity compared to homologous vaccination. Conclusions: There is a lack of data from further challenge studies to support the efficacy of the rMVA-RSV preF vaccine in terms of protection, but our findings demonstrate a favorable immunogenicity profile of the rMVA-RSV preF vaccine, supporting its further development as a promising RSV vaccine candidate.<\/jats:p>","DOI":"10.3390\/vaccines14040317","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:08:34Z","timestamp":1775030914000},"page":"317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb\/c Mice"],"prefix":"10.3390","volume":"14","author":[{"given":"Jinhui","family":"Miao","sequence":"first","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing 100024, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feixia","family":"Gao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing 100024, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongshan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"He","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Biological Products, Shanghai 200051, China"},{"name":"State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing 100024, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, Z.W., Zhang, Q., Li, J.R., Xie, N.H., Zheng, Q.M., Lai, Y.Z., and Zhang, X.Y. (2025). Contribution of Respiratory Syncytial Virus to Burden of Lower Respiratory Tract Infections: A Global Analysis of 204 Countries and Territories, 1990\u20132021. Trop. Med. Infect. Dis., 10.","DOI":"10.3390\/tropicalmed10080223"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijid.2023.08.008","article-title":"Global Burden and Trends of Respiratory Syncytial Virus Infection across Different Age Groups from 1990 to 2019: A Systematic Analysis of the Global Burden of Disease 2019 Study","volume":"135","author":"Du","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/0018578719836646","article-title":"The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review","volume":"55","author":"Avery","year":"2020","journal-title":"Hosp. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of Rsv in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices-United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR-Morb. Mortal. Wkly. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-World Effectiveness of Nirsevimab against Respiratory Syncytial Virus Disease in Infants: A Systematic Review and Meta-Analysis","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gatt, D., Martin, I., AlFouzan, R., and Moraes, T.J. (2023). Prevention and Treatment Strategies for Respiratory Syncytial Virus (Rsv). Pathogens, 12.","DOI":"10.3390\/pathogens12020154"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40121-024-01079-x","article-title":"The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review","volume":"14","author":"Debbag","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11262-006-0064-x","article-title":"Respiratory Syncytial Virus (Rsv) Evades the Human Adaptive Immune System by Skewing the Th1\/Th2 Cytokine Balance toward Increased Levels of Th2 Cytokines and Ige, Markers of Allergy-a Review","volume":"33","author":"Becker","year":"2006","journal-title":"Virus Genes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1073\/pnas.81.24.7683","article-title":"Nucleotide-Sequence of the Gene Encoding the Fusion (F) Glycoprotein of Human Respiratory Syncytial Virus","volume":"81","author":"Collins","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing Antibodies against the Preactive Form of Respiratory Syncytial Virus Fusion Protein Offer Unique Possibilities for Clinical Intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I.J.M., Widjojoatmodjo, M.N., Zahn, R., Schuitemaker, H., and McLellan, J.S. (2015). A Highly Stable Prefusion Rsv F Vaccine Derived from Structural Analysis of the Fusion Mechanism. Nat. Commun., 6.","DOI":"10.1038\/ncomms9143"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative Structure-Based Improvement of a Fusion-Glycoprotein Vaccine against Rsv","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Alandijany, T.A., and Qashqari, F.S. (2025). Evaluating the Efficacy, Safety, and Immunogenicity of Fda-Approved Rsv Vaccines: A Systematic Review of Arexvy, Abrysvo, and Mresvia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1624007"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","article-title":"Early Safety Findings among Persons Aged \u226560 Years Who Received a Respiratory Syncytial Virus Vaccine-United States, May 3, 2023-April 14, 2024","volume":"73","author":"Hause","year":"2024","journal-title":"Mmwr-Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent Rsv Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mahase, E. (2024). Fda Pauses All Infant Rsv Vaccine Trials after Rise in Severe Illnesses. BMJ, 387.","DOI":"10.1136\/bmj.q2852"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent Rsv Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified Vaccinia Virus Ankara (Mva) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"Volume 97","author":"Kielian","year":"2017","journal-title":"Advances in Virus Research"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Orlova, O.V., Glazkova, D.V., Bogoslovskaya, E.V., Shipulin, G.A., and Yudin, S.M. (2022). Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications. Vaccines, 10.","DOI":"10.3390\/vaccines10091516"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0264-410X(99)00257-1","article-title":"Priming and Boosting Immunity to Respiratory Syncytial Virus by Recombinant Replication-Defective Vaccinia Virus Mva","volume":"18","author":"Wyatt","year":"1999","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2003.10.010","article-title":"Vaccination of Infant Macaques with a Recombinant Modified Vaccinia Virus Ankara Expressing the Respiratory Syncytial Virus F and G Genes Does Not Predispose for Immunopathology","volume":"22","author":"Wyatt","year":"2004","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2004.05.015","article-title":"Protective and Disease-Enhancing Immune Responses Induced by Recombinant Modified Vaccinia Ankara (Mva) Expressing Respiratory Syncytial Virus Proteins","volume":"23","author":"Olszewska","year":"2004","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Endt, K., Wollmann, Y., Haug, J., Bernig, C., Feigl, M., Heiseke, A., Kalla, M., Hochrein, H., Suter, M., and Chaplin, P. (2022). A Recombinant Mva-Based Rsv Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection against Rsv Infection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.841471"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jordan, E., Jenkins, V., Silbernagl, G., Ch\u00e1vez, M.P.V., Schmidt, D., Schnorfeil, F., Schultz, S., Chen, L.D.Y., Salgado, F., and Jacquet, J.M. (2024). A Multivalent Rsv Vaccine Based on the Modified Vaccinia Ankara Vector Shows Moderate Protection against Disease Caused by Rsv in Older Adults in a Phase 3 Clinical Study. Vaccine, 42.","DOI":"10.1101\/2024.07.22.24309971"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rhee, C.H., Her, M., and Jeong, W. (2022). Modified Vaccinia Virus Ankara as a Potential Biosafety Level 2 Surrogate for African Swine Fever Virus in Disinfectant Efficacy Tests. Pathogens, 11.","DOI":"10.3390\/pathogens11030320"},{"key":"ref_31","first-page":"5.13.1","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"89","author":"Wyatt","year":"2017","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Deng, L., Cao, H., Li, G., Zhou, K., Fu, Z., Zhong, J., Wang, Z., and Yang, X. (2025). Progress on Respiratory Syncytial Virus Vaccine Development and Evaluation Methods. Vaccines, 13.","DOI":"10.3390\/vaccines13030304"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bouzya, B., Rouxel, R.N., Sacconnay, L., Mascolo, R., Nols, L., Quique, S., Fran\u00e7ois, L., Atas, A., Warter, L., and Dezutter, N. (2023). Immunogenicity of an As01-Adjuvanted Respiratory Syncytial Virus Prefusion F (Rsvpref3) Vaccine in Animal Models. npj Vaccines, 8.","DOI":"10.1038\/s41541-023-00729-4"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schaerlaekens, S., Jacobs, L., Stobbelaar, K., Cos, P., and Delputte, P. (2024). All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?. Vaccines, 12.","DOI":"10.3390\/vaccines12010097"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumg\u00e4rtner, W., Sutter, G., Osterhaus, A., and Prajeeth, C.K. (2023). Induction of Humoral and Cell-Mediated Immunity to the Ns1 Protein of Tbev with Recombinant Influenza Virus and Mva Affords Partial Protection against Lethal Tbev Infection in Mice. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1177324"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Om, K., Paquin-Proulx, D., Montero, M., Peachman, K., Shen, X.Y., Wieczorek, L., Beck, Z., Weiner, J.A., Kim, D., and Li, Y.F. (2020). Adjuvanted Hiv-1 Vaccine Promotes Antibody-Dependent Phagocytic Responses and Protects against Heterologous Shiv Challenge. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008764"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/22221751.2021.1951624","article-title":"The Combined Vaccination Protocol of DNA\/Mva Expressing Zika Virus Structural Proteins as Efficient Inducer of T and B Cell Immune Responses","volume":"10","author":"Poderoso","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Marcos-Villar, L., Perdiguero, B., L\u00f3pez-Bravo, M., Zamora, C., Sin, L., Alvarez, E., Sorzano, C.O.S., S\u00e1nchez-Cord\u00f3n, P.J., Casasnovas, J.M., and Astorgano, D. (2024). Heterologous Mrna\/Mva Delivering Trimeric-Rbd as Effective Vaccination Regimen against SARS-CoV-2: Covarna Consortium. Emerg. Microbes Infect., 13.","DOI":"10.1080\/22221751.2024.2387906"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing Epitopes on the Respiratory Syncytial Virus Fusion Glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.vaccine.2021.12.043","article-title":"Immunogenicity and Protective Efficacy of Adenoviral and Subunit Rsv Vaccines Based on Stabilized Prefusion F Protein in Pre-Clinical Models","volume":"40","author":"Saeland","year":"2022","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., Yassine, H.M., Moin, S.M., Killikelly, A.M., and Chuang, G.Y. (2015). Prefusion F-Specific Antibodies Determine the Magnitude of Rsv Neutralizing Activity in Human Sera. Sci. Transl. Med., 7.","DOI":"10.1126\/scitranslmed.aac4241"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"van Erp, E.A., Luytjes, W., Ferwerda, G., and van Kasteren, P.B. (2019). Fc-Mediated Antibody Effector Functions during Respiratory Syncytial Virus Infection and Disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00548"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Bian, L.J., Zhao, H.T., Liu, Y.L., Lu, J.C., Liu, D.W., Zhang, K., Song, Y.S., Luo, Y.S., and Jiang, C.L. (2020). Respiratory Syncytial Virus F Subunit Vaccine with As02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in Balb\/C Mice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.526965"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bian, L.J., Zheng, Y., Guo, X.H., Li, D.D., Zhou, J.Y., Jing, L.Y., Chen, Y., Lu, J.C., Zhang, K., and Jiang, C.L. (2022). Intramuscular Inoculation of As02-Adjuvanted Respiratory Syncytial Virus (Rsv) F Subunit Vaccine Shows Better Efficiency and Safety Than Subcutaneous Inoculation in Balb\/C Mice. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.938598"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/infdis\/jiab611","article-title":"Phase 1\/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults with Concomitant Inactivated Influenza Vaccine","volume":"225","author":"Falsey","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chai, P., Shi, Y., Yu, J., Liu, X., Yang, M., Li, D., Li, K., Li, S., Kong, X., and Zhang, Q. (2025). An Oral Vaccine Based on the Ad5 Vector with a Double-Stranded Rna Adjuvant Protects Mice against Respiratory Syncytial Virus. Int. Immunopharmacol., 146.","DOI":"10.1016\/j.intimp.2024.113970"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Miao, J., Li, X.J., Li, Y.W., Mao, L.J., Suo, W.K., and Lan, J.M. (2025). Single-Dose Intranasal Immunization with Chad68-Vectored Prefusion F Vaccines Confers Sustained Protection against Respiratory Syncytial Virus in Murine Models. Vaccines, 13.","DOI":"10.3390\/vaccines13050528"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cid\/cit209","article-title":"Heterologous (\u201cNonspecific\u201d) and Sex-Differential Effects of Vaccines: Epidemiology, Clinical Trials, and Emerging Immunologic Mechanisms","volume":"57","author":"Flanagan","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10096-018-03449-z","article-title":"Opposite Effects of Vaccinia and Modified Vaccinia Ankara on Trained Immunity","volume":"38","author":"Blok","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.4049\/jimmunol.1100764","article-title":"Multiple Cd4+ T Cell Subsets Produce Immunomodulatory Il-10 during Respiratory Syncytial Virus Infection","volume":"187","author":"Weiss","year":"2011","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sun, J., Cardani, A., Sharma, A.K., Laubach, V.E., Jack, R.S., M\u00fcller, W., and Braciale, T.J. (2011). Autocrine Regulation of Pulmonary Inflammation by Effector T-Cell Derived Il-10 during Infection with Respiratory Syncytial Virus. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002173"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Loebbermann, J., Schnoeller, C., Thornton, H., Durant, L., Sweeney, N.P., Schuijs, M., O\u2019Garra, A., Johansson, C., and Openshaw, P.J. (2012). Il-10 Regulates Viral Lung Immunopathology during Acute Respiratory Syncytial Virus Infection in Mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032371"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.coviro.2015.06.003","article-title":"Animal Models of Respiratory Syncytial Virus Infection and Disease","volume":"13","author":"Sacco","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","article-title":"Animal Models of Respiratory Syncytial Virus Infection","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:12:46Z","timestamp":1775189566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/4\/317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["vaccines14040317"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14040317","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}